8P9X image
Entry Detail
PDB ID:
8P9X
Keywords:
Title:
Vitamin D receptor complex with Xe4Me agonist ligand
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2023-06-06
Release Date:
2024-06-26
Method Details:
Experimental Method:
Resolution:
2.15 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 65 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Vitamin D3 receptor A
Chain IDs:A
Chain Length:302
Number of Molecules:1
Biological Source:Danio rerio
Polymer Type:polypeptide(L)
Description:Nuclear receptor coactivator 2
Chain IDs:B
Chain Length:13
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
A vitamin D-based strategy overcomes chemoresistance in prostate cancer.
Br.J.Pharmacol. 181 4279 4293 (2024)
PMID: 38982588 DOI: 10.1111/bph.16492

Abstact

BACKGROUND AND PURPOSE Castration-resistant prostate cancer (CRPC) is a common male malignancy that requires new therapeutic strategies due to acquired resistance to its first-line treatment, docetaxel. The benefits of vitamin D on prostate cancer (PCa) progression have been previously reported. This study aimed to investigate the effects of vitamin D on chemoresistance in CRPC. EXPERIMENTAL APPROACH Structure function relationships of potent vitamin D analogues were determined. The combination of the most potent analogue and docetaxel was explored in chemoresistant primary PCa spheroids and in a xenograft mouse model derived from a patient with a chemoresistant CRPC. KEY RESULTS Here, we show that Xe4MeCF3 is more potent than the natural ligand to induce vitamin D receptor (VDR) transcriptional activities and that it has a larger therapeutic window. Moreover, we demonstrate that VDR agonists restore docetaxel sensitivity in PCa spheroids. Importantly, Xe4MeCF3 reduces tumour growth in a chemoresistant CRPC patient-derived xenograft. In addition, this treatment targets signalling pathways associated with cancer progression in the remaining cells. CONCLUSION AND IMPLICATIONS Taken together, these results unravel the potency of VDR agonists to overcome chemoresistance in CRPC and open new avenues for the clinical management of PCa.

Legend

Protein

Chemical

Disease

Primary Citation of related structures